Recruitment Messages for Current Smokers Recently Diagnosed With Cancer

NCT ID: NCT05471284

Last Updated: 2022-07-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-11

Study Completion Date

2019-04-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study was to conduct a pilot factorial randomized trial to identify the message frames that are most effective in promoting participation in a tobacco treatment trial for current smokers recently diagnosed with cancer. To do so, we used a multimethod approach to evaluate 3 different message frames across evaluation, effectiveness, and outcome measures. We combine findings from a message design experiment with textual analytic software to provide a holistic understanding of how message frames may or may not differentially affect tobacco treatment trial participation within the context of a cancer diagnosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: A cancer diagnosis can catalyze motivation to quit smoking. Tobacco treatment trials offer cessation resources but have low accrual rates. Digital outreach may improve accrual, but knowledge of how best to recruit smokers with recent diagnoses is limited.

Objective: This study aims to identify the message frames that were most effective in promoting intent to talk to a physician about participating in a tobacco treatment trial for smokers recently diagnosed with cancer.

Methods: From February to April 2019, current smokers diagnosed within the past 24 months were recruited from a national web-based panel for a multimethod pilot randomized trial (N=99). Participants were randomized to a 2×3 plus control factorial design that tested 3 unique message frames: proximal versus distal threats of smoking, costs of continued smoking versus benefits of quitting, and gains of participating versus losses of not participating in a tobacco treatment trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Smoking Health Behavior

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

The control condition was a kernel message that included study information present in all conditions but did not include any of the message factors.

Group Type SHAM_COMPARATOR

Control

Intervention Type BEHAVIORAL

Does not include any of the three message factors.

Proximal x Cost x Loss

Message frame: proximal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.

Group Type EXPERIMENTAL

Proximal

Intervention Type BEHAVIORAL

The first factor tested framing of the near, proximal threat of continued smoking.

Cost

Intervention Type BEHAVIORAL

Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.

Loss

Intervention Type BEHAVIORAL

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.

Proximal x Cost x Gain

Message frame: proximal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.

Group Type EXPERIMENTAL

Proximal

Intervention Type BEHAVIORAL

The first factor tested framing of the near, proximal threat of continued smoking.

Cost

Intervention Type BEHAVIORAL

Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.

Gain

Intervention Type BEHAVIORAL

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Proximal x Benefit x Gain

Message frame: proximal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.

Group Type EXPERIMENTAL

Proximal

Intervention Type BEHAVIORAL

The first factor tested framing of the near, proximal threat of continued smoking.

Benefit

Intervention Type BEHAVIORAL

Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.

Gain

Intervention Type BEHAVIORAL

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Proximal x Benefit x Loss

Message frame: proximal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.

Group Type EXPERIMENTAL

Proximal

Intervention Type BEHAVIORAL

The first factor tested framing of the near, proximal threat of continued smoking.

Benefit

Intervention Type BEHAVIORAL

Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.

Loss

Intervention Type BEHAVIORAL

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.

Distal x Cost x Gain

Message frame: distal threats of smoking, cost of continued smoking, and gain of participating in a tobacco treatment trial.

Group Type EXPERIMENTAL

Distal

Intervention Type BEHAVIORAL

The first factor tested framing of the long-term, distal threat of continued smoking.

Cost

Intervention Type BEHAVIORAL

Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.

Gain

Intervention Type BEHAVIORAL

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Distal x Cost x Loss

Message frame: distal threats of smoking, cost of continued smoking, and loss of not participating in a tobacco treatment trial.

Group Type EXPERIMENTAL

Distal

Intervention Type BEHAVIORAL

The first factor tested framing of the long-term, distal threat of continued smoking.

Cost

Intervention Type BEHAVIORAL

Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.

Loss

Intervention Type BEHAVIORAL

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.

Distal x Benefit x Loss

Message frame: distal threats of smoking, benefits of quitting, and loss of not participating in a tobacco treatment trial.

Group Type EXPERIMENTAL

Distal

Intervention Type BEHAVIORAL

The first factor tested framing of the long-term, distal threat of continued smoking.

Benefit

Intervention Type BEHAVIORAL

Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.

Loss

Intervention Type BEHAVIORAL

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.

Distal x Benefit x Gain

Message frame: distal threats of smoking, benefits of quitting, and gain of participating in a tobacco treatment trial.

Group Type EXPERIMENTAL

Distal

Intervention Type BEHAVIORAL

The first factor tested framing of the long-term, distal threat of continued smoking.

Benefit

Intervention Type BEHAVIORAL

Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.

Gain

Intervention Type BEHAVIORAL

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Proximal

The first factor tested framing of the near, proximal threat of continued smoking.

Intervention Type BEHAVIORAL

Distal

The first factor tested framing of the long-term, distal threat of continued smoking.

Intervention Type BEHAVIORAL

Cost

Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.

Intervention Type BEHAVIORAL

Benefit

Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.

Intervention Type BEHAVIORAL

Loss

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.

Intervention Type BEHAVIORAL

Gain

The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.

Intervention Type BEHAVIORAL

Control

Does not include any of the three message factors.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Speak and understand English
* A recent cancer diagnosis (within the past 24 months)
* 18 years or older
* Report any cigarette use within the past 30 days

Exclusion Criteria

* Do not speak or understand English
* Have not been diagnosed with cancer within the past 24 months
* Below the age of 18
* Does not report any cigarette use within the past 30 days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tufts University

OTHER

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role collaborator

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role collaborator

University of Oklahoma

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jordan Neil, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

TSET Health Promotion Research Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jordan Neil

Oklahoma City, Oklahoma, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Neil JM, Senecal C, Ballini L, Chang Y, Goshe B, Flores E, Ostroff JS, Park ER. A Multimethod Evaluation of Tobacco Treatment Trial Recruitment Messages for Current Smokers Recently Diagnosed With Cancer: Pilot Factorial Randomized Controlled Trial. JMIR Cancer. 2022 Aug 24;8(3):e37526. doi: 10.2196/37526.

Reference Type DERIVED
PMID: 36001378 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018P002035

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Message Framing for Telephone Quitline Callers
NCT00589277 COMPLETED PHASE1/PHASE2
Tobacco Use Treatment in Cancer Patients
NCT03482583 COMPLETED PHASE4